Two biopharmaceutical companies took a step forward this week with their pipelines for advanced breast cancer.
NeoPharm to Investigate Treatment for Deadly Lung Disease
The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.
Clarient Acquires AGI In All-Stock Merger
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).
ThromboGenics Starts Phase II Trial for Macular Degeneration Therapy
ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD).
Cytori’s (NASDAQ: CYTX) Natural Celution for Breast Reconstruction
Cytori Therapeutics is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.
Vertex to Sell 1.5 Million Shares
Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.
Potential Hepatitis C Breakthrough for Santaris
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
